Literature DB >> 30294897

The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity.

Thomas P C Chu1, Matthew J Grainge1, Timothy R Card1,2.   

Abstract

BACKGROUND: Inflammatory bowel disease (IBD) increases the risk of venous thromboembolism. AIMS: To determine when patients are at high risk of thromboembolic events, including after major surgery, and to guide timing of thromboprophylaxis.
METHODS: Each IBD patient from Clinical Practice Research Datalink, linked with Hospital Episode Statistics, was matched to up to five non-IBD patients in this cohort study. We examined their risk of thromboembolism in hospital and within 6 weeks after leaving hospital, with or without undergoing major surgery, and while ambulant. Hazard ratios were estimated using Cox regression, with adjustment for age, sex, body mass index, smoking and history of malignancy or thromboembolism.
RESULTS: Overall 23 046 IBD patients had a thromboembolic risk 1.74-times (95% CI = 1.55-1.96) higher than 106 795 non-IBD patients. Among ambulant patients, the thromboembolic risk was raised during acute (hazard ratio = 3.94, 2.79-5.57) or chronic disease activity (3.97, 2.90-5.45) but their absolute risk remained below 5/1000 person-years. The hazard ratio for thromboembolism among in-patients not undergoing major surgery was 1.13 (0.63-2.02), compared to 2.43 (1.20-4.92) among surgical patients, with a near doubling of absolute risk associated with surgery (59.5/1000 person-years, compared with 31.1 without surgery). The absolute risk remained elevated within 6 weeks after leaving hospital (18.6/1000 person-years in IBD patients after surgery).
CONCLUSIONS: IBD patients are at an increased risk of venous thromboembolism. Absolute risks are raised during active disease, when in hospital, and after leaving hospital following major surgery.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30294897     DOI: 10.1111/apt.15010

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  7 in total

1.  Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease.

Authors:  Adam S Faye; Kenneth W Hung; Kimberly Cheng; John W Blackett; Anna Sophia Mckenney; Adam R Pont; Jianhua Li; Garrett Lawlor; Benjamin Lebwohl; Daniel E Freedberg
Journal:  Inflamm Bowel Dis       Date:  2020-08-20       Impact factor: 5.325

2.  Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases.

Authors:  Adam S Faye; Timothy Wen; Ashwin N Ananthakrishnan; Simon Lichtiger; Gilaad G Kaplan; Alexander M Friedman; Garrett Lawlor; Jason D Wright; Frank J Attenello; William J Mack; Benjamin Lebwohl
Journal:  Clin Gastroenterol Hepatol       Date:  2019-07-20       Impact factor: 11.382

3.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Authors:  Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

4.  The risk of venous thromboembolic events in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Konstantinos D Arvanitakis; Alexandra D Arvanitaki; Christos D Karkos; Elias Α Zintzaras; Georgios S Germanidis
Journal:  Ann Gastroenterol       Date:  2021-05-27

Review 5.  Reducing Perioperative Risks of Surgery in Crohn's Disease.

Authors:  Wolfgang Reindl; Anne Kerstin Thomann; Christian Galata; Peter Kienle
Journal:  Visc Med       Date:  2019-11-12

6.  Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study.

Authors:  Su Young Kim; Yeon Seo Cho; Hyun-Soo Kim; Jung Kuk Lee; Hee Man Kim; Hong Jun Park; Hyunil Kim; Jihoon Kim; Dae Ryong Kang
Journal:  Gut Liver       Date:  2021-11-18       Impact factor: 4.321

7.  Editorial: increasing IBD prevalence and its complications in the context of the COVID-19 pandemic.

Authors:  Samantha Jane Benson-Pope; Richard B Gearry
Journal:  Aliment Pharmacol Ther       Date:  2020-05-14       Impact factor: 8.171

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.